CuATSM Therapy May Slow ALS Progression, Improving Cognition and Respiration in Patients, Phase 1 Trial Shows

CuATSM Therapy May Slow ALS Progression, Improving Cognition and Respiration in Patients, Phase 1 Trial Shows

CuATSM, one of the lead investigational therapies of Collaborative Medicinal Development (CMD), may slow disease progression and improve the respiratory and cognitive function of patients with amyotrophic lateral sclerosis (ALS), a Phase 1 trial shows.

The findings of the multicenter, open-label, dose-finding study (NCT02870634) were announced by the company’s CEO, Craig Rosenfeld, during a presentation at the 29th International Symposium on ALS/MND, held from Dec. 7 to 9, 2018, in Glasgow, Scotland.

CuATSM is a small artificial molecule that is able to deliver copper to cells containing damaged mitochondria, the cell compartments responsible for the production of energy. Damaged mitochondria are considered a hallmark of several neurodegenerative diseases, including ALS, Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease.

Since CuATSM only delivers copper to damaged cells, leaving healthy cells unharmed, the idea is to use this molecule to target only unhealthy cells and reduce the damage caused by the disease.

In October 2016, CMD launched the first-in-man clinical trial for CuATSM in patients with sporadic and familial ALS to determine the best dose, and study its pharmacokinetic properties.

During the first two phases of the study, patients were divided into several groups to determine the best and safest dose for CuATSM (recommended Phase 2 dose). In the third phase, the goal was to confirm patients’ tolerability to treatment and evaluate its efficacy.

According to a press release, data from the third phase of the study showed that disease progression slowed significantly in patients with sporadic ALS after 24 weeks of treatment with CuATSM at the recommended Phase 2 dose, as measured by the Revised ALS Functional Rating Scale (ALSFRS-R) score (-0.29 points/month vs the expected -1.02 points/month).

In addition, patients’ respiratory function assessed by forced vital capacity (FVC) and cognitive function by the Edinburgh Cognitive and Behavioral ALS Screen (ECAS) score also showed a significant improvement after 24 weeks of treatment with CuATSM (+1.1 % predicted/month vs -2.24 % predicted/month for FVC, and +10 points vs no changes for ECAS).

As expected, patients treated with lower doses of CuATSM experienced minor improvements in ALSFRS-R score and FVC compared with those treated with higher doses over the 24 weeks. This observation is in line with data from preclinical studies in mouse models of ALS, showing that CuATSM acted in a dose-dependent manner when administered to the animals.

CMD is now planning to launch a randomized, placebo-controlled clinical trial for CuATSM to confirm these results.

CuATSM treatment should not be confused with taking copper supplements, which can be toxic at even moderate doses, and do not help people with ALS, scientists say.

18 comments

    • Joana Carvalho says:

      Hi Bibi. More clinical trials are needed before we reach that point, I am afraid. Hopefully more news about these upcoming studies will be available soon.

    • Joana Carvalho says:

      Hi Seamus. Not yet, only that CMD is planning to go ahead and launch a new clinical trial to confirm these data. Hopefully it will happen soon.

  1. Terry says:

    I have a friend diagnosed with MND. How do I go about to see if he can participate in the trial or when will access to this drug be available on the market?

  2. Maryse Gauthier says:

    J’espère dans un avenir prochain que cette nouvelle recherche fera une différence significative pour tous ceux qui ont cette maladie dévastatrice la SLA et je remercie de tout cœur tous ceux qui comme mon mari ont participe a une recherche quelconque et ceux qui comme lui ont perdu la pire bataille de leur vie mais qui malgré tout ont garde espoir jusqu’à la fin dans la recherche.

  3. Paul says:

    Hi Joana, If the phase 1 trial had proven success why wouldn’t this be available under the “right to try” law or at a minimum, do some more trials in the US? For many diagnosed with ALS, another couple of years to study this may be too late. I’d be happy to take it now with just the hope that it could help.

    • Joana Carvalho says:

      Hi Paul. I understand where you are coming from, but unfortunately clinical trials are not that straightforward. Even for investigational drugs to be available under the “right to try” law there are is a number of criteria that need to be met before patients are allowed to have access to them: https://www.fda.gov/ForPatients/Other/ucm625115.htm
      I am not saying there won’t be any future trials in the U.S. On the contrary, based on these promising Phase 1 results, I would say new trials should happen in the future. As for the when that will happen, it is still unclear at this point. I am sorry, I know that is not what you and everyone else here would like to hear, but that’s all we can say for now.

  4. Janet Brisky says:

    I would like to be notify when stage 2 starts and if I could be in the trial. I was dx in 2018 with ALS and have foot drop, some balance problems and slight weakness in 1 finger. I have no problem with my breathing.

    Thank You

Leave a Comment

Your email address will not be published. Required fields are marked *